Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R E Walker

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
Clinical Immunology (Orlando, Fla.)|April 5, 2001
Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansionK D Miller, K Spooner, B R Herpin, et al.
Nature Medicine|May 1, 1997
HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapiesM Connors, J A Kovacs, S Krevat, et al.
The Journal of Infectious Diseases|July 1, 1996
Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1R E Walker, K M Spooner, G Kelly, et al.
The Journal of Infectious Diseases|April 1, 1996
Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: results of a phase I/II trialJ A Kovacs, C Bechtel, R T Davey, et al.
The Journal of Infectious Diseases|September 9, 2000
Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expressionJ A Kovacs, H Imamichi, S Vogel, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1997
Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infectionM A Polis, S C Piscitelli, S Vogel, et al.
AIDS (London, England)|November 24, 1999
Lymph node architecture preceding and following 6 months of potent antiviral therapy: follicular hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patientJ M Orenstein, M Feinberg, C Yoder, et al.
The Journal of Infectious Diseases|March 9, 1999
A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infectionR T Davey, D G Chaitt, J M Albert, et al.
European Journal of Immunology|July 24, 2001
Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapyJ A Kovacs, S Vogel, J A Metcalf, et al.
Nature Medicine|July 14, 1998
Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adultsR E Walker, C S Carter, L Muul, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Clinical Immunology (Orlando, Fla.)|April 5, 2001
Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansionK D Miller, K Spooner, B R Herpin, et al.
Nature Medicine|May 1, 1997
HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapiesM Connors, J A Kovacs, S Krevat, et al.
The Journal of Infectious Diseases|July 1, 1996
Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1R E Walker, K M Spooner, G Kelly, et al.
The Journal of Infectious Diseases|April 1, 1996
Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: results of a phase I/II trialJ A Kovacs, C Bechtel, R T Davey, et al.
The Journal of Infectious Diseases|September 9, 2000
Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expressionJ A Kovacs, H Imamichi, S Vogel, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1997
Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infectionM A Polis, S C Piscitelli, S Vogel, et al.
AIDS (London, England)|November 24, 1999
Lymph node architecture preceding and following 6 months of potent antiviral therapy: follicular hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patientJ M Orenstein, M Feinberg, C Yoder, et al.
The Journal of Infectious Diseases|March 9, 1999
A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infectionR T Davey, D G Chaitt, J M Albert, et al.
European Journal of Immunology|July 24, 2001
Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapyJ A Kovacs, S Vogel, J A Metcalf, et al.
Nature Medicine|July 14, 1998
Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adultsR E Walker, C S Carter, L Muul, et al.
Pageof 9